Developments in the Erectile Dysfunction Markets

NEW YORK, August 28, 2017 /PRNewswire/ --

A research report by Life Science Intelligence (LSI), Erectile dysfunction (ED) is estimated to affect more than 150 million men worldwide and the number of men with ED is expected to double by the year 2030. Although most cases are not reported, it is estimated that more than 30 million men affected in the United States. The report indicates that ED is more common in men older than age 65, most men older than the age of 40 experience occasional difficulty and it is estimated that more than 50% of men older than the age of 40 report periodic episodes of ED. Creative Medical Technology Holdings, Inc. (OTC: CELZ), Easton Pharmaceuticals, Inc. (OTC: EAPH), VIVUS, Inc. (NASDAQ: VVUS), Apricus Biosciences, Inc. (NASDAQ: APRI), ViaDerma, Inc. (OTC: VDRM),

A new report by Visiongain forecasts that the world market for sexual dysfunction drugs will reach $7.7 billion in 2019, or rising further to 2026. The market will be stimulated by ageing populations, rising incidence of cardiovascular and metabolic disorders, new drug delivery technologies, emerging test techniques and the rising female sexual dysfunction drugs submarket. Sandra Wenas, a senior pharmaceutical industry analyst in Visiongain stated, "We believe that there will be positive changes in the way societies perceive male and female sexual dysfunctions. Increased awareness and more self reporting will expand the size of patient populations. Presently there is still divided opinion on whether female sexual dysfunction is a physiological disease that needs medication or whether it is a psychological condition."

Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) earlier today announced that, "completion of enrollment in the Company's clinical trial assessing safety and efficacy of its CaverstemTM procedure to treat erectile dysfunction in patients who do not respond to currently available treatments. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.

"The CaverstemTM procedure, which uses the patient's own bone marrow derived stem cells to induce arterial and venous regeneration, is an outpatient procedure able to be conducted by Urologists in their medical facilities. We are using a patient's own cells and we do not manipulate the stem cells through the use of chemicals, growth factors or expansion and have experienced no procedure-related safety issues," said Dr. Thomas Ichim Co-Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.

The clinical trial covering patients ages 18 to 80 received Institutional Review Board (IRB) approval in December 2016. The trial is sponsored by us based on our patented technology and is conducted by Dr. Jacob Rajfer, Principal Investigator and Los Angeles Biomedical Institute at Harbor - UCLA Hospital in Torrance, CA.  

"I am pleased with the expedience and efficiency at which enrollment was reached. As someone who regularly sees patients suffering from treatment non-responsive erectile dysfunction, I am excited to see the development of a novel approach to treating this condition using the patient's own natural regenerative processes," said Dr. Alexander Gershman, member of the Company's Scientific Advisory Board and Director of Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center."

"We are very fortunate to work with the expert team at Los Angeles Biomedical Institute - UCLA/Harbor Hospital who have done an outstanding job with subject recruitment, screening, treatment and follow-up.  We firmly believe that we are on schedule for commercialization of the Caverstem TM procedure through publication and presentation of trial results, marketing, licensing, training and sales in 2018," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.

Easton Pharmaceuticals, Inc. (OTC: EAPH) s is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. According to the company's Product and Market Overview, "When it comes to treating pain, sexual dysfunction and other disease states that emanate from structures of the body below the skin, topical therapy is not effective unless the therapeutic agent can cross the outer layer of the skin (stratum corneum) which acts as a protective barrier. This layer consists of numerous dead cells and cells in transition, which collectively forms an effective barrier to penetration of substances, such as bacteria, in the air or in water. Thus the stratum comeum plays an important role in protecting the body from invasion by harmful substances."

VIVUS, Inc. (NASDAQ: VVUS) is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs.  STENDRA or avanafil is approved in the U.S. by the FDA for the treatment of erectile dysfunction.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian-Pacific Rim countries.  On August 3^rd, the company reported financial results for the quarter ended June 30, 2017. 

Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has a product called Vitaros, a candidate in the United States for the treatment of erectile dysfunction.  Vitaros is a topically-applied cream formulation of alprostadil, which dilates blood vessels, combined with a proprietary permeation enhancer NexACT, which directly increases blood flow to the penis, causing an erection. Vitaros is currently in development in the U.S. and approved and commercialized in certain countries outside of the U.S. Allergan owns the rights to Vitaros in the U.S. and in September 2015, the company entered into an agreement with Allergan to license the U.S. development and commercialization rights for Vitaros. 

ViaDerma, Inc. (OTC: VDRM) is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. The company's lead product candidate, Vitastem,  broad spectrum tetracycline-based topical antibiotic with proven results. Vitastem could be used in a variety of potential markets, including erectile dysfunction, burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, and pain management.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated three thousand dollars for financial news dissemination and pr services by a non-affiliate third party for creative medical technology holdings, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com .

For further information:

Media Contact: info@financialbuzz.com , +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com